Media Thread, page-7843

Apologies if already posted, could not find above... Dec 30, 2022 Pharmaceutical Technology...Data Insights
As IMU-131 moves closer to clinical approval, what is the likelihood that the drug will be approved?

IMU-131 is under clinical development by Imugene and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect IMU-131’s likelihood of approval (LoA) and phase transition for Adenocarcinoma Of The Gastroesophageal Junction took place on 29 Jun 2022, which

increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 29 Jun 2022

increased IMU-131’s LoA and PTSR for Gastric Cancer.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their IMU-131 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.